Finska - finski - Fimea (Suomen lääkevirasto)

leo pharma a/s - azelaic acid - geeli - 150 mg/g - atselaiinihappo

Finska - finski - Fimea (Suomen lääkevirasto)

laboratoire francais du fractionnement et des biotechnologies - human fibrinogen - injektio/infuusiokuiva-aine ja liuotin, liuosta varten - 1.5 g - fibrinogeeni

Finska - finski - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - ascorbic acid, biotin, colecalciferol, cyanocobalamin, riboflavin sodium fosfate, nicotinamide, pyridoxine hydrochloride, retinol palmitate, thiamine hydrochloride, all-rac-alfa-tocopherol, pantothenic acid, all-rac-phytomenadione, folic acid hydrate - infuusiokuiva-aine, liuosta varten - 932 mg - vitamiinit

Europska Unija - finski - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiset aineet - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Europska Unija - finski - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - immunoseerumit ja immunoglobuliinit, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. katso kohdat 4. 4 ja 5.

Finska - finski - Ecolab

ecolab deutschland gmbh -

Finska - finski - Ecolab

ecolab deutschland gmbh -

Finska - finski - Ecolab

ecolab deutschland gmbh -

Europska Unija - finski - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, systemaattinen - immunosuppressantit - benlysta on tarkoitettu lisälääkkeenä potilailla, iältään 5 vuotta ja vanhemmat, joilla on aktiivinen, autoantibody positiivinen systeeminen lupus erythematosus (sle) korkea taudin aktiivisuus (e. positiivinen anti-dsdna ja alhainen täydentää) huolimatta tavanomaista hoitoa. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Europska Unija - finski - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinibi (monohydraattina) - leukemia, myeloidi - antineoplastic agents, protein kinase inhibitors - bosulif on tarkoitettu aikuisille potilaille, joilla on:hiljattain diagnosoitu kroonisen vaiheen (cp) philadelphia-kromosomi-positiivinen krooninen myelooinen leukemia (ph+ kml). cp, akseleraatiovaiheen (ap), ja blastikriisivaiheen (bp) ph+ kml on aikaisemmin hoidettu yksi tai useampi tyrosiinikinaasin estäjä(s) [tki(s)] ja joille imatinibin, nilotinibin ja dasatinibin ei katsota asianmukaista hoitoa vaihtoehtoja.